Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

UroGen Pharma (URGN) Invested Capital (2016 - 2025)

UroGen Pharma (URGN) has disclosed Invested Capital for 10 consecutive years, with $19.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Invested Capital rose 321.81% year-over-year to $19.5 million, compared with a TTM value of $19.5 million through Dec 2025, up 321.81%, and an annual FY2025 reading of $19.5 million, up 321.81% over the prior year.
  • Invested Capital was $19.5 million for Q4 2025 at UroGen Pharma, up from -$115.4 million in the prior quarter.
  • Across five years, Invested Capital topped out at $76.5 million in Q1 2021 and bottomed at -$138.4 million in Q2 2023.
  • Average Invested Capital over 5 years is -$31.4 million, with a median of -$40.5 million recorded in 2022.
  • The sharpest move saw Invested Capital tumbled 1162.18% in 2022, then skyrocketed 321.81% in 2025.
  • Year by year, Invested Capital stood at $8.4 million in 2021, then crashed by 1162.18% to -$89.4 million in 2022, then rose by 27.02% to -$65.2 million in 2023, then skyrocketed by 86.5% to -$8.8 million in 2024, then surged by 321.81% to $19.5 million in 2025.
  • Business Quant data shows Invested Capital for URGN at $19.5 million in Q4 2025, -$115.4 million in Q3 2025, and -$93.4 million in Q2 2025.